Altheos

About:

Altheos was a biopharmaceutical company focused on the development of small molecule drugs.

Website: http://altheos.net

Top Investors: Novo Holdings, Canaan Partners, Life Science Angels, Bay City Capital, Atheneos Ventures

Description:

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs. Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.